AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in pulmonary diseases.
AlterNet on MSNOpinion
Christa Pike's nightmarish ordeal wasn't an anomaly
Over the course of two hours, witnesses watched and listened as Christa Pike cried, whimpered and snored through Tennessee’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results